New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.

@article{Weaver1994NewRG,
  title={New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.},
  author={William D. Weaver and JUL. HARTMANN and Jeffrey L Anderson and P. Sudhakar Reddy and John Sobolski and Arthur A. Sasahara},
  journal={Journal of the American College of Cardiology},
  year={1994},
  volume={24 5},
  pages={1242-8}
}
OBJECTIVES Three dosage regimens of a new recombinant glycosylated prourokinase (A-74187) were evaluated by measuring coronary artery patency at 90 min in patients with acute myocardial infarction. BACKGROUND Prourokinase is a thrombolytic drug with unique pharmacologic properties that may be clinically advantageous. METHODS Aspirin (325 mg), intravenous heparin and prourokinase (60- or 80-mg monotherapy or 60 mg "primed" with a preceding bolus dose of 250,000 IU of recombinant urokinase… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved.

Journal of the American College of Cardiology • 2016
View 13 Excerpts
Highly Influenced

Primary percutaneous coronary intervention.

The New England journal of medicine • 2008

Management of Acute Coronary Syndromes

CORONARY SYNDROMES, CONTEMPORARY CARDIOLOGY, CORONARY SYNDROMFS
Contemporary Cardiology • 1999
View 3 Excerpts

Similar Papers

Loading similar papers…